Cargando…

Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis

OBJECTIVES: To investigate the validity and feasibility of the Juvenile Arthritis Disease Activity Score (JADAS) in the routine clinical setting for all juvenile idiopathic arthritis (JIA) disease categories and explore whether exclusion of the erythrocyte sedimentation rate (ESR) from JADAS (the ‘J...

Descripción completa

Detalles Bibliográficos
Autores principales: Mcerlane, Flora, Beresford, Michael W, Baildam, Eileen M, Chieng, S E Alice, Davidson, Joyce E, Foster, Helen E, Gardner-Medwin, Janet, Lunt, Mark, Wedderburn, Lucy R, Thomson, Wendy, Hyrich, Kimme L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841758/
https://www.ncbi.nlm.nih.gov/pubmed/23256951
http://dx.doi.org/10.1136/annrheumdis-2012-202031
_version_ 1782292843725848576
author Mcerlane, Flora
Beresford, Michael W
Baildam, Eileen M
Chieng, S E Alice
Davidson, Joyce E
Foster, Helen E
Gardner-Medwin, Janet
Lunt, Mark
Wedderburn, Lucy R
Thomson, Wendy
Hyrich, Kimme L
author_facet Mcerlane, Flora
Beresford, Michael W
Baildam, Eileen M
Chieng, S E Alice
Davidson, Joyce E
Foster, Helen E
Gardner-Medwin, Janet
Lunt, Mark
Wedderburn, Lucy R
Thomson, Wendy
Hyrich, Kimme L
author_sort Mcerlane, Flora
collection PubMed
description OBJECTIVES: To investigate the validity and feasibility of the Juvenile Arthritis Disease Activity Score (JADAS) in the routine clinical setting for all juvenile idiopathic arthritis (JIA) disease categories and explore whether exclusion of the erythrocyte sedimentation rate (ESR) from JADAS (the ‘JADAS3’) influences correlation with single markers of disease activity. METHODS: JADAS-71, JADAS-27 and JADAS-10 were determined at baseline for an inception cohort of children with JIA in the Childhood Arthritis Prospective Study. JADAS3-71, JADAS3-27 and JADAS3-10 were determined using an identical formula but with exclusion of ESR. Correlation of JADAS with JADAS3 and single measures of disease activity/severity were determined by category. RESULTS: Of 956 eligible children, sufficient data were available to calculate JADAS-71, JADAS-27 and JADAS-10 at baseline in 352 (37%) and JADAS3 in 551 (58%). The median (IQR) JADAS-71, JADAS-27 and JADAS-10 for all 352 children was 11 (5.9–18), 10.4 (5.7–17) and 11 (5.9–17.3), respectively. Median JADAS and JADAS3 varied significantly with the category (Kruskal–Wallis p=0.0001), with the highest values in children with polyarticular disease patterns. Correlation of JADAS and JADAS3 across all categories was excellent. Correlation of JADAS71 with single markers of disease activity/severity was good to moderate, with some variation across the categories. With the exception of ESR, correlation of JADAS3-71 was similar to correlation of JADAS-71 with the same indices. CONCLUSIONS: This study is the first to apply JADAS to all categories of JIA in a routine clinical setting in the UK, adding further information about the feasibility and construct validity of JADAS. For the majority of categories, clinical applicability would be improved by exclusion of the ESR.
format Online
Article
Text
id pubmed-3841758
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-38417582013-12-02 Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis Mcerlane, Flora Beresford, Michael W Baildam, Eileen M Chieng, S E Alice Davidson, Joyce E Foster, Helen E Gardner-Medwin, Janet Lunt, Mark Wedderburn, Lucy R Thomson, Wendy Hyrich, Kimme L Ann Rheum Dis Clinical and Epidemiological Research OBJECTIVES: To investigate the validity and feasibility of the Juvenile Arthritis Disease Activity Score (JADAS) in the routine clinical setting for all juvenile idiopathic arthritis (JIA) disease categories and explore whether exclusion of the erythrocyte sedimentation rate (ESR) from JADAS (the ‘JADAS3’) influences correlation with single markers of disease activity. METHODS: JADAS-71, JADAS-27 and JADAS-10 were determined at baseline for an inception cohort of children with JIA in the Childhood Arthritis Prospective Study. JADAS3-71, JADAS3-27 and JADAS3-10 were determined using an identical formula but with exclusion of ESR. Correlation of JADAS with JADAS3 and single measures of disease activity/severity were determined by category. RESULTS: Of 956 eligible children, sufficient data were available to calculate JADAS-71, JADAS-27 and JADAS-10 at baseline in 352 (37%) and JADAS3 in 551 (58%). The median (IQR) JADAS-71, JADAS-27 and JADAS-10 for all 352 children was 11 (5.9–18), 10.4 (5.7–17) and 11 (5.9–17.3), respectively. Median JADAS and JADAS3 varied significantly with the category (Kruskal–Wallis p=0.0001), with the highest values in children with polyarticular disease patterns. Correlation of JADAS and JADAS3 across all categories was excellent. Correlation of JADAS71 with single markers of disease activity/severity was good to moderate, with some variation across the categories. With the exception of ESR, correlation of JADAS3-71 was similar to correlation of JADAS-71 with the same indices. CONCLUSIONS: This study is the first to apply JADAS to all categories of JIA in a routine clinical setting in the UK, adding further information about the feasibility and construct validity of JADAS. For the majority of categories, clinical applicability would be improved by exclusion of the ESR. BMJ Publishing Group 2013-12 2012-12-20 /pmc/articles/PMC3841758/ /pubmed/23256951 http://dx.doi.org/10.1136/annrheumdis-2012-202031 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Clinical and Epidemiological Research
Mcerlane, Flora
Beresford, Michael W
Baildam, Eileen M
Chieng, S E Alice
Davidson, Joyce E
Foster, Helen E
Gardner-Medwin, Janet
Lunt, Mark
Wedderburn, Lucy R
Thomson, Wendy
Hyrich, Kimme L
Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis
title Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis
title_full Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis
title_fullStr Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis
title_full_unstemmed Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis
title_short Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis
title_sort validity of a three-variable juvenile arthritis disease activity score in children with new-onset juvenile idiopathic arthritis
topic Clinical and Epidemiological Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841758/
https://www.ncbi.nlm.nih.gov/pubmed/23256951
http://dx.doi.org/10.1136/annrheumdis-2012-202031
work_keys_str_mv AT mcerlaneflora validityofathreevariablejuvenilearthritisdiseaseactivityscoreinchildrenwithnewonsetjuvenileidiopathicarthritis
AT beresfordmichaelw validityofathreevariablejuvenilearthritisdiseaseactivityscoreinchildrenwithnewonsetjuvenileidiopathicarthritis
AT baildameileenm validityofathreevariablejuvenilearthritisdiseaseactivityscoreinchildrenwithnewonsetjuvenileidiopathicarthritis
AT chiengsealice validityofathreevariablejuvenilearthritisdiseaseactivityscoreinchildrenwithnewonsetjuvenileidiopathicarthritis
AT davidsonjoycee validityofathreevariablejuvenilearthritisdiseaseactivityscoreinchildrenwithnewonsetjuvenileidiopathicarthritis
AT fosterhelene validityofathreevariablejuvenilearthritisdiseaseactivityscoreinchildrenwithnewonsetjuvenileidiopathicarthritis
AT gardnermedwinjanet validityofathreevariablejuvenilearthritisdiseaseactivityscoreinchildrenwithnewonsetjuvenileidiopathicarthritis
AT luntmark validityofathreevariablejuvenilearthritisdiseaseactivityscoreinchildrenwithnewonsetjuvenileidiopathicarthritis
AT wedderburnlucyr validityofathreevariablejuvenilearthritisdiseaseactivityscoreinchildrenwithnewonsetjuvenileidiopathicarthritis
AT thomsonwendy validityofathreevariablejuvenilearthritisdiseaseactivityscoreinchildrenwithnewonsetjuvenileidiopathicarthritis
AT hyrichkimmel validityofathreevariablejuvenilearthritisdiseaseactivityscoreinchildrenwithnewonsetjuvenileidiopathicarthritis
AT validityofathreevariablejuvenilearthritisdiseaseactivityscoreinchildrenwithnewonsetjuvenileidiopathicarthritis